Advanced search    

Search: authors:"Kohei Shitara"

23 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors

, Astellas, MSD, Merck Serono, Pfizer, Novartis, Celgene, Merrimack, Yuhan Pharmaceuticals, BMS, Ono Pharmaceutical Co., Ltd., Daiichi Sankyo, AstraZeneca, Takeda, and Hansoh Pharmaceuticals. Kohei Shitara has

First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors

: Toshihiko Doi, Kohei Shitara, Hideaki Takahashi, Kiyotaka Yoh, Makoto Ueno, Satoshi Kobayashi, Manabu Morimoto, Takuji Okusaka, Hideki Ueno, Chigusa Morizane, Naohiro Okano, Fumio Nagashima, Junji Furuse ... . Data collection: Toshihiko Doi, Kohei Shitara, Hideaki Takahashi, Kiyotaka Yoh, Makoto Ueno, Satoshi Kobayashi, Manabu Morimoto, Takuji Okusaka, Hideki Ueno, Chigusa Morizane, Naohiro Okano, Fumio

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial

BackgroundIn the ABSOLUTE trial, weekly nanoparticle albumin-bound paclitaxel (w-nab-PTX) showed non-inferiority to weekly solvent-based paclitaxel (w-sb-PTX) for overall survival (OS). Thus, w-nab-PTX might be an option for second-line chemotherapy in advanced gastric cancer (AGC). However, predictive factors for efficacies of these agents have not been evaluated.MethodsPatients...

NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis

ObjectivesThis study was an open-label phase I study to confirm the safety and tolerability of NC-6004 in combination with gemcitabine in Japanese patients with advanced solid tumors and to assess the PK effects of NC-6004 monotherapy.MethodsThis phase I study used a 3 + 3 design to determine the maximum tolerated dose (MTD) and recommended dose of NC-6004 combined with...

Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials

Background The prognosis of patients with gastrointestinal stromal tumor (GIST) after the failure of standard therapies is poor with supportive care alone. Guidelines recommend clinical trials, and patients with good performance status following standard therapies are often eligible for phase I clinical trials of investigational agents; however, there are no detailed reports on...

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

Background TAS-102 (trifluridine and tipiracil hydrochloride; a novel combination oral nucleoside anti-tumor agent) has recently received regulatory approval for patients with refractory metastatic colorectal cancer (mCRC). Internal review of data at a single-institution showed a trend towards better overall survival (OS) for patients who experienced chemotherapy-induced...

Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)

A previous dose-escalation study of sulfasalazine (SSZ), an inhibitor of cystine-glutamate exchange transporter xc (–), in the variant form of CD44 (CD44v)-positive cancer stem cells (CSCs) suggested that administration of SSZ induces the reduction of CD44v-positive cells and intracellular reduced glutathione (GSH) levels in patients with advanced gastric cancer (AGC). Here we...

Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG

The role of multidisciplinary treatment including surgery for liver metastases from gastric cancer (LMGC) is controversial. Studies to answer this clinical question are increasing in number, but all published data thus far are based on retrospective analyses with limited sample sizes. Thus, the European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal...

Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy

BackgroundThe Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC) demonstrated a survival benefit by adjuvant S-1 monotherapy in patients who had undergone curative resection of stage II/III gastric cancer, but there is still a need to improve the efficacy of treatment of stage III disease. We investigated the tolerability and safety of S-1 and oxaliplatin as adjuvant...

Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer

Background The correlation between progression-free survival (PFS) or time to progression (TTP) and overall survival (OS) has been evaluated in patients with advanced gastric cancer (AGC) who received first-line chemotherapy. No corresponding analysis has been done in patients who have undergone second-line chemotherapy. Methods We evaluated the correlation between PFS, TTP...

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer

Background The mutation in KRAS exon 2 is a validated biomarker of resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). Several reports have confirmed associations of other RAS mutations with resistance to anti-EGFR therapy. However, the impact of BRAF and PIK3CA mutations on the efficacy of anti-EGFR therapy remains...

Gastrointestinal bleeding after aortic surgery: a case report

Introduction An aortoenteric fistula is a communication between the aorta and an adjacent loop of the bowel. Here we report a case with this rare complication with typical herald bleeding. Case report A 66-year-old man underwent elective repair of a large supra-renal abdominal aortic aneurysm and returned 6 months later to our clinic after experiencing a melena with hematochezia...

Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis

Background There are few data on the efficacy of combination chemotherapy with a fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer (AGC) complicated by peritoneal metastasis, especially massive ascites. Methods We retrospectively evaluated the efficacy and safety of a fluoropyrimidine (S-1 or capecitabine) plus cisplatin as first-line...

Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment

Background The purpose of this study was to evaluate the impact of human epidermal growth factor receptor 2 (HER2) status and trastuzumab treatment on the prognosis of patients with advanced gastric cancer (AGC). Methods We retrospectively analyzed 364 AGC patients who received systemic chemotherapy. To evaluate the impact of trastuzumab exposure during any type of chemotherapy...

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients

BackgroundThis study was conducted to investigate whether human epidermal growth factor receptor 2 (HER2) status, epidermal growth factor receptor (EGFR) status, and c-MET status are independent prognostic factors for advanced gastric cancer patients who received standard chemotherapy.MethodUnresectable or recurrent gastric or gastroesophageal junction cancer patients with...

Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer

examination of reference lists from original and review articles. Two investigators (Kohei Shitara and Keitaro Matsuo) extracted data in accordance with the Quality of Reporting of Meta-analyses (QUORUM

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

and was similar between treatment arms in both populations. The overall survival hazard ratio was 0.88 (95 % - & Kohei Shitara confidence interval, 0.60–1.28) in the Japanese population and 0.73 (95 ... Pharmaceutical, Merck Serono, Bayer, and Chugai Pharmaceutical. Yasushi Omuro, Taito Esaki, Naotoshi Sugimoto, Hirofumi Yasui, Seigo Yukisawa, Kohei Shitara, Yoshito Komatsu, Takao Tamura, Masahiro Gotoh

A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)

Akira Tsuburaya 0 Satoshi Morita Yasuhiro Kodera Michiya Kobayashi Kohei Shitara Kensei Yamaguchi Takaki Yoshikawa 0 Kazuhiro Yoshida Shigefumi Yoshino Jun-ichi Sakamoto 0 Department of

Suspected paclitaxel-induced pneumonitis

We report two patients with advanced gastric cancer with suspected paclitaxel-induced interstitial pneumonitis. Case 1, a 66-year-old man with recurrent gastric cancer, was treated weekly with paclitaxel. After 11 administrations of paclitaxel, he developed a nonproductive cough and dyspnea. Computed tomography (CT) scan showed extensive bilateral areas of ground-glass...

Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis

Background In investigations of the effectiveness of surgery and adjuvant chemotherapy for gastric cancers, overall survival (OS) is considered the gold standard endpoint. However, the disadvantage of using OS as the endpoint is that it requires an extended follow-up period. We sought to investigate whether disease-free survival (DFS) is a valid surrogate for OS in trials of...